Neoclease

Neoclease is an early-stage biotech leveraging a proprietary generative AI platform to engineer novel, custom nucleases for therapeutic gene editing. The company's core technology combines synthetic biology with AI trained on known nuclease data to design enzymes with high specificity and efficacy, particularly for targets in tissues traditionally inaccessible to CRISPR. With a lead program targeting Parkinson's disease and a platform approach to over 6,000 monogenic diseases, Neoclease is positioning itself at the intersection of AI and next-generation genetic medicine. The company is privately held, pre-revenue, and in the pre-clinical stage of development.

Proprietary generative AI platform trained on known nuclease data to design custom, miniaturized gene-editing nucleases for specific therapeutic targets, integrated with synthetic biology for enzyme engineering.

Neoclease competes in the crowded gene-editing therapeutics space, dominated by public companies using CRISPR-Cas systems (e.g., CRISPR Therapeutics, Intellia). Its differentiation claims are superior specificity, custom design, and efficacy in tissues inaccessible to CRISPR. It also competes with other AI-driven drug discovery platforms applying machine learning to biologics design.